Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

Major clinical research advances in gynecologic cancer in 2018.

Kim M, Suh DH, Lee KH, Eom KY, Toftdahl NG, Mirza MR, Kim JW.

J Gynecol Oncol. 2019 Mar;30(2):e18. doi: 10.3802/jgo.2019.30.e18. Review.

2.

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.

Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, Zola P, Salutari V.

J Ovarian Res. 2019 Jan 28;12(1):9. doi: 10.1186/s13048-019-0484-6. Review.

3.

Screening of Cervical Cancer with Self-Collected Cervical Samples and Next-Generation Sequencing.

Fan Y, Meng Y, Yang S, Wang L, Zhi W, Lazare C, Cao C, Wu P.

Dis Markers. 2018 Nov 14;2018:4826547. doi: 10.1155/2018/4826547. eCollection 2018. Review.

4.

ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.

Caumanns JJ, Wisman GBA, Berns K, van der Zee AGJ, de Jong S.

Biochim Biophys Acta Rev Cancer. 2018 Dec;1870(2):176-184. doi: 10.1016/j.bbcan.2018.07.005. Epub 2018 Jul 17. Review.

5.

siRNA in ovarian cancer - Delivery strategies and targets for therapy.

van den Brand D, Mertens V, Massuger LFAG, Brock R.

J Control Release. 2018 Aug 10;283:45-58. doi: 10.1016/j.jconrel.2018.05.012. Epub 2018 May 16. Review.

6.

Major clinical research advances in gynecologic cancer in 2017.

Suh DH, Kim M, Lee KH, Eom KY, Kjeldsen MK, Mirza MR, Kim JW.

J Gynecol Oncol. 2018 Mar;29(2):e31. doi: 10.3802/jgo.2018.29.e31. Review.

7.

Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.

Cheng X, Zhang L, Chen Y, Qing C.

J Ovarian Res. 2017 Nov 13;10(1):75. doi: 10.1186/s13048-017-0369-5. Review.

8.

Current advances in endocrine therapy options for premenopausal women with hormone receptor positive breast cancer.

Gemignani ML, Hetzel DJ.

Gynecol Oncol. 2017 Oct;147(1):153-157. doi: 10.1016/j.ygyno.2017.06.023. Epub 2017 Jun 26. Review. No abstract available.

9.

Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.

Jang JYA, Yanaihara N, Pujade-Lauraine E, Mikami Y, Oda K, Bookman M, Ledermann J, Shimada M, Kiyokawa T, Kim BG, Matsumura N, Kaku T, Kuroda T, Nagayoshi Y, Kawabata A, Iida Y, Kim JW, Quinn M, Okamoto A.

J Gynecol Oncol. 2017 Jul;28(4):e54. doi: 10.3802/jgo.2017.28.e54. Review.

10.

Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.

Suh DH, Kim M, Kim K, Kim HJ, Lee KH, Kim JW.

J Gynecol Oncol. 2017 May;28(3):e45. doi: 10.3802/jgo.2017.28.e45. Epub 2017 Mar 24. Review.

11.

Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment.

Rojas V, Hirshfield KM, Ganesan S, Rodriguez-Rodriguez L.

Int J Mol Sci. 2016 Dec 15;17(12). pii: E2113. Review.

12.

The rise of genomic profiling in ovarian cancer.

Previs RA, Sood AK, Mills GB, Westin SN.

Expert Rev Mol Diagn. 2016 Dec;16(12):1337-1351. Review.

13.

A perverse quality incentive in surgery: implications of reimbursing surgeons less for doing laparoscopic surgery.

Fader AN, Xu T, Dunkin BJ, Makary MA.

Surg Endosc. 2016 Nov;30(11):4665-4667. Epub 2016 Oct 17. Review.

14.

Major clinical research advances in gynecologic cancer in 2015.

Suh DH, Kim M, Kim HJ, Lee KH, Kim JW.

J Gynecol Oncol. 2016 Nov;27(6):e53. doi: 10.3802/jgo.2016.27.e53. Review.

15.

Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κB Signaling for Cancer Treatment.

Zeligs KP, Neuman MK, Annunziata CM.

Clin Cancer Res. 2016 Sep 1;22(17):4302-8. doi: 10.1158/1078-0432.CCR-15-1374. Epub 2016 Jul 15. Review.

16.

AKT in cancer: new molecular insights and advances in drug development.

Mundi PS, Sachdev J, McCourt C, Kalinsky K.

Br J Clin Pharmacol. 2016 Oct;82(4):943-56. doi: 10.1111/bcp.13021. Epub 2016 Jun 27. Review.

17.

Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Sherman ME, Drapkin RI, Horowitz NS, Crum CP, Friedman S, Kwon JS, Levine DA, Shih IeM, Shoupe D, Swisher EM, Walker J, Trabert B, Greene MH, Samimi G, Temkin SM, Minasian LM.

Cancer Prev Res (Phila). 2016 Sep;9(9):713-20. doi: 10.1158/1940-6207.CAPR-15-0384. Epub 2016 May 24. Review.

18.

Optimal primary therapy of ovarian cancer.

Bookman MA.

Ann Oncol. 2016 Apr;27 Suppl 1:i58-i62. doi: 10.1093/annonc/mdw088. Review.

19.

Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.

Liu J, Westin SN.

Gynecol Oncol. 2016 Apr;141(1):65-71. doi: 10.1016/j.ygyno.2016.01.003. Review.

20.

Gene-expression signatures in ovarian cancer: Promise and challenges for patient stratification.

Konecny GE, Winterhoff B, Wang C.

Gynecol Oncol. 2016 May;141(2):379-385. doi: 10.1016/j.ygyno.2016.01.026. Epub 2016 Jan 28. Review.

Supplemental Content

Loading ...
Support Center